Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly

Nancy K Gillis, PharmD, Markus Ball, PhD, Qing Zhang, MD, YuLong Zhao, PhD, Sean Yoder, M.S, Maria E. Balasis, Tania E. Mesa, David Sallman, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Alan F List, MD, Howard L McLeod, PharmD, Dana E Rollison, PhD, Eric Padron, MD

Blood (2016) 128 (22): 295.

https://doi.org/10.1182/blood.V128.22.295.295

Published: 2016

Journal Articles

A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia

Kendra L. Sweet, MD, Rami S. Komrokji, MD, Eric Padron, MD, Christopher L Cubitt, PhD, Leyla Khavarian, Alan F List, MD, David Sallman, MD, Daniel Sullivan, Julio C Chavez, MD, Bijal D. Shah, MD, Jeffrey E. Lancet, MD

Blood (2016) 128 (22): 4040.

https://doi.org/10.1182/blood.V128.22.4040.4040

Published: 2016

Journal Articles

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Kathy L Mcgraw, PhD, Johnny Nguyen, Najla Alali, MS, Jinming Song, MD PhD, David Sallman, MD, Eric Padron, MD, Jeffrey E. Lancet, MD, Daihui Qin, P.K. Epling-Burnette, PhD, Lynn C. Moscinski, MD, Rami S. Komrokji, MD, Alan F List, MD, Ling Zhang, MD

Blood (2016) 128 (22): 4305.

https://doi.org/10.1182/blood.V128.22.4305.4305

Published: 2016

Journal Articles

Epigenetic Profiling in High-Risk MDS and AML Patients Identifies Pre-Treatment Methylation Patterns That Indicate Response to Hypomethylating Agents: A Pilot Study

Chetasi Talati, MD, Adam Marsh, Kylie Baggett, Najla Al-Ali, Kendra L. Sweet, MD, David Sallman, MD, Rami S. Komrokji, MD, Alan F. List, MD, Eric Padron, MD, Jeffrey E. Lancet, MD

Blood (2016) 128 (22): 2885.

https://doi.org/10.1182/blood.V128.22.2885.2885

Published: 2016

Journal Articles

Characterization of Myelodysplastic Syndromes (MDS) with T-Cell Large Granular Lymphocyte Proliferations (LGL)

Christa Roe, MA, BS, RN, OCN, Najla Alali, MS, Eric Padron, MD, Pearlie K Burnette, PhD, Kendra L. Sweet, MD, David Sallman, MD, Lubomir Sokol, MD PhD, Jeffrey E. Lancet, MD, Alan F. List, MD, Rami S Komrokji, MD

Blood (2016) 128 (22): 113.

https://doi.org/10.1182/blood.V128.22.113.113

Published: 2016

Journal Articles

NLRP3 Inflammasome-Derived ASC Specks Are a Diagnostic Biomarker for Myelodysplastic Syndromes (MDS)

Ashley A Basiorka, Zhenjun Ma, PhD, Kathy L Mcgraw, PhD, David Sallman, MD, Brittany A Irvine, Najla H Al Ali, Eric Padron, MD, Javier Pinilla-Ibarz, MD PhD, Rami S. Komrokji, MD, Lubomir Sokol, Sheng Wei, Alan F List, MD

Blood (2016) 128 (22): 2005.

https://doi.org/10.1182/blood.V128.22.2005.2005

Published: 2016

Journal Articles

Characterization of Cytogenetic Abnormalities in Myelofibrosis and Relationship to Clinical Outcome

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla H Al Ali, Eric Padron, MD, David Sallman, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1937.

https://doi.org/10.1182/blood.V128.22.1937.1937

Published: 2016

Journal Articles

Clinical Utility of Molecular Profiling in Higher Risk MDS Treated with Azacitidine: Can We Tailor Therapy Accordingly?

David Sallman, MD, Eric Padron, MD, Jinming Song, MD PhD, Mohammad Omar Hussaini, MD, Christine Vaupel, PhD, Najla H Al Ali, Jeffrey E. Lancet, MD, Jeff Hall, PhD, Alan F List, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1984.

https://doi.org/10.1182/blood.V128.22.1984.1984

Published: 2016

Journal Articles

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome

Megan Melody, BA, MS, Najla H Al Ali, Ling Zhang, MD, Hanadi Ramadan, BA, Eric Padron, MD, David Sallman, MD, Kendra L. Sweet, MD, Jeffrey E Lancet, MD, Alan F List, MD, John M. Bennett, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1985.

https://doi.org/10.1182/blood.V128.22.1985.1985

Published: 2016

Journal Articles

Mutation Landscape in Myelofibrosis: Assessment of Frequency and Correlation with Clinical Factors and Outcomes

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla H Al Ali, Eric Padron, MD, David Sallman, MD, Jinming Song, MD PhD, Ling Zhang, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1946.

https://doi.org/10.1182/blood.V128.22.1946.1946

Published: 2016

Journal Articles

Validation of Genomic-Based Risk Models in Myelofibrosis and Proposal of Age-Independent Disease-Specific Models

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla Al Ali, Eric Padron, MD, David Sallman, MD, Jinming Song, MD PhD, Ling Zhang, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1947.

https://doi.org/10.1182/blood.V128.22.1947.1947

Published: 2016

Journal Articles

Racial Disparities in Patients with Myelodysplastic Syndrome (MDS): Clinical and Molecular Depiction

Hanadi Ramadan, BA, Megan Melody, BA, MS, Amanda Steele, Najla H Al Ali, Eric Padron, MD, David Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Alan F List, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 1997.

https://doi.org/10.1182/blood.V128.22.1997.1997

Published: 2016

Journal Articles

Treatment-Related Morbidity and Mortality Associated with Remission Induction in Adolescent and Young Adult (AYA) Versus Young Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Cory Michael Vela, PharmD, Viet Q. Ho, PharmD, RPh, BCOP, Justina Ofori Frimpong, PharmD, BCOP, Bryan Brinda, Pharm.D., Timothy George, Pharm.D., BCOP, Kendra L. Sweet, MD, Eric Padron, MD, David Sallman, MD, Alan F List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 5167.

https://doi.org/10.1182/blood.V128.22.5167.5167

Published: 2016

Journal Articles

Comparing Eras: Assessing Treatment Trends before and after Ruxolitinib Approval

Andrew Kuykendall, MD, Chetasi Talati, MD, Najla Al Ali, Eric Padron, MD, David Sallman, MD, Jeffrey E. Lancet, MD, Kendra L. Sweet, MD, Alan F. List, Kenneth S. Zuckerman, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 3124.

https://doi.org/10.1182/blood.V128.22.3124.3124

Published: 2016

Journal Articles

Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Can We Alter the Natural History?

Kaitlin Hendrix, NP, MSN, Najla Alali, MS, Eric Padron, MD, David Sallman, MD, Alan F. List, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD

Blood (2016) 128 (22): 3125.

https://doi.org/10.1182/blood.V128.22.3125.3125

Published: 2016

Journal Articles

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, John Barnard, PhD, Najla Alali, MS, Amy E. DeZern, MD MHS, Eric Padron, MD, David Sallman, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, Jaime Fensterl, Guillermo Garcia-Manero, MD, David P. Steensma, MD, Alan F List, MD

Blood (2016) 128 (22): 4322.

https://doi.org/10.1182/blood.V128.22.4322.4322

Published: 2016

Journal Articles

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Mohamed A. Kharfan-Dabaja, MD, Rami S. Komrokji, MD, Qing Zhang, PhD, David Sallman, MD, Asmita Mishra, MD, Najla H. Al Ali, BDS, MSc, Taiga Nishihori, MD, Teresa Field, MD, PhD, Karma Z Salem, MD, Janelle Perkins, PharmD, Ling Zhang, MD, Lynn C. Moscinski, MD, Hugo F. Fernandez, MD, Jeffrey E Lancet, MD, Alan F. List, MD, Claudio Anasetti, MD, Eric Padron, MD

Blood (2015) 126 (23): 4382.

https://doi.org/10.1182/blood.V126.23.4382.4382

Published: 2015

Journal Articles

P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes

Nguyen Johnny, MD, Kathy L McGraw, PhD, Rami S. Komrokji, MD, David Sallman, MD, Najla H. Al Ali, BDS, MSc, Eric Padron, MD, Jeffrey E Lancet, MD, Lynn C. Moscinski, MD, Alan F. List, MD, Ling Zhang, MD

Blood (2015) 126 (23): 4121.

https://doi.org/10.1182/blood.V126.23.4121.4121

Published: 2015

Journal Articles

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

Blood (2015) 126 (23): 907.

https://doi.org/10.1182/blood.V126.23.907.907

Published: 2015

Journal Articles

NLRP3 Inflammosome Polymorphisms Are Enriched in Myelodysplastic Syndrome Patients with Autoimmune Disorders

Syed A Mian, BSc, M.Phil, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Aytug Kizilors, PhD, Kathy L McGraw, PhD, Shahram Kordasti, MD PhD, Stephan Menzel, PhD, Alexander e Smith, PhD, Pilar Perezabellan, BSc, David Sallman, MD, Alan F. List, MD, Ghulam J Mufti, FRCP, FRCPath

Blood (2015) 126 (23): 1659.

https://doi.org/10.1182/blood.V126.23.1659.1659

Published: 2015

NARROW

Clonal Hematopoiesis Is Associated with Therapy-Related Myeloid Malignancies in the Elderly

A Phase I Study of Selinexor in Combination with Daunorubicin and Cytarabine in Patients with Newly Diagnosed Poor-Risk Acute Myeloid Leukemia

EZH2 Protein Expression Is Decreased in MDS and MDS/MPN and Correlated with EZH2 Mutation Status, Chromosomal 7 Abnormalities and Clinical Outcome

Epigenetic Profiling in High-Risk MDS and AML Patients Identifies Pre-Treatment Methylation Patterns That Indicate Response to Hypomethylating Agents: A Pilot Study

Characterization of Myelodysplastic Syndromes (MDS) with T-Cell Large Granular Lymphocyte Proliferations (LGL)

NLRP3 Inflammasome-Derived ASC Specks Are a Diagnostic Biomarker for Myelodysplastic Syndromes (MDS)

Characterization of Cytogenetic Abnormalities in Myelofibrosis and Relationship to Clinical Outcome

Clinical Utility of Molecular Profiling in Higher Risk MDS Treated with Azacitidine: Can We Tailor Therapy Accordingly?

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndrome

Mutation Landscape in Myelofibrosis: Assessment of Frequency and Correlation with Clinical Factors and Outcomes

Validation of Genomic-Based Risk Models in Myelofibrosis and Proposal of Age-Independent Disease-Specific Models

Racial Disparities in Patients with Myelodysplastic Syndrome (MDS): Clinical and Molecular Depiction

Treatment-Related Morbidity and Mortality Associated with Remission Induction in Adolescent and Young Adult (AYA) Versus Young Adult Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Comparing Eras: Assessing Treatment Trends before and after Ruxolitinib Approval

Myelodysplastic/Myeloproliferative Neoplasms Unclassified (MDS/MPN-U) Overlap: Can We Alter the Natural History?

Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium

TP53 and IDH2 Somatic Mutations Are Associated with Poor Outcomes Following Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

P53 Protein Overexpression By Immunohistochemical Staining Is Correlated with TP53 Mutation Burden and Adverse Clinical Outcome in Myelodysplastic Syndromes

Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee

NLRP3 Inflammosome Polymorphisms Are Enriched in Myelodysplastic Syndrome Patients with Autoimmune Disorders

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only